Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Working Capital Changes (2022 - 2025)

Historic Other Working Capital Changes for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$596000.0.

  • Atara Biotherapeutics' Other Working Capital Changes rose 2696.08% to -$596000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.3 million, marking a year-over-year decrease of 42931.3%. This contributed to the annual value of -$20.3 million for FY2024, which is 16679.72% down from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Other Working Capital Changes is -$596000.0, which was up 2696.08% from -$14.4 million recorded in Q2 2025.
  • Atara Biotherapeutics' Other Working Capital Changes' 5-year high stood at $40.3 million during Q4 2023, with a 5-year trough of -$79.1 million in Q1 2025.
  • In the last 4 years, Atara Biotherapeutics' Other Working Capital Changes had a median value of -$2.9 million in 2023 and averaged -$6.8 million.
  • As far as peak fluctuations go, Atara Biotherapeutics' Other Working Capital Changes skyrocketed by 30311.45% in 2024, and later tumbled by 103310.92% in 2025.
  • Atara Biotherapeutics' Other Working Capital Changes (Quarter) stood at $40.0 million in 2022, then rose by 0.87% to $40.3 million in 2023, then tumbled by 130.34% to -$12.2 million in 2024, then skyrocketed by 95.13% to -$596000.0 in 2025.
  • Its last three reported values are -$596000.0 in Q3 2025, -$14.4 million for Q2 2025, and -$79.1 million during Q1 2025.